umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Using germline variants to estimate glioma and subtype risks
Visa övriga samt affilieringar
2019 (Engelska)Ingår i: Neuro-Oncology, ISSN 1522-8517, E-ISSN 1523-5866, Vol. 21, nr 4, s. 451-461Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Twenty-five single nucleotide polymorphisms (SNPs) are associated with adult diffuse glioma risk. We hypothesized that the inclusion of these 25 SNPs with age at diagnosis and sex could estimate risk of glioma as well as identify glioma subtypes.

Methods: Case-control design and multinomial logistic regression were used to develop models to estimate the risk of glioma development while accounting for histologic and molecular subtypes. Case-case design and logistic regression were used to develop models to predict isocitrate dehydrogenase (IDH) mutation status. A total of 1273 glioma cases and 443 controls from Mayo Clinic were used in the discovery set, and 852 glioma cases and 231 controls from UCSF were used in the validation set. All samples were genotyped using a custom Illumina OncoArray.

Results: Patients in the highest 5% of the risk score had more than a 14-fold increase in relative risk of developing an IDH mutant glioma. Large differences in lifetime absolute risk were observed at the extremes of the risk score percentile. For both IDH mutant 1p/19q non-codeleted glioma and IDH mutant 1p/19q codeleted glioma, the lifetime risk increased from almost null to 2.3% and almost null to 1.7%, respectively. The SNP-based model that predicted IDH mutation status had a validation concordance index of 0.85.

Conclusions: These results suggest that germline genotyping can provide new tools for the initial management of newly discovered brain lesions. Given the low lifetime risk of glioma, risk scores will not be useful for population screening; however, they may be useful in certain clinically defined high-risk groups.

Ort, förlag, år, upplaga, sidor
Oxford University Press, 2019. Vol. 21, nr 4, s. 451-461
Nyckelord [en]
classification, genotype, glioblastoma, glioma, polygenic
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-158081DOI: 10.1093/neuonc/noz009ISI: 000462632100006PubMedID: 30624711OAI: oai:DiVA.org:umu-158081DiVA, id: diva2:1304917
Forskningsfinansiär
NIH (National Institute of Health), P50CA108961NIH (National Institute of Health), P30 CA15083NIH (National Institute of Health), RC1NS068222ZNIH (National Institute of Health), R01CA52689NIH (National Institute of Health), P50CA097257NIH (National Institute of Health), R01CA126831NIH (National Institute of Health), R01CA139020NIH (National Institute of Health), R01CA163687NIH (National Institute of Health), R25CA112355Tillgänglig från: 2019-04-15 Skapad: 2019-04-15 Senast uppdaterad: 2019-04-15Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Melin, Beatrice S.

Sök vidare i DiVA

Av författaren/redaktören
Melin, Beatrice S.
Av organisationen
Institutionen för strålningsvetenskaper
I samma tidskrift
Neuro-Oncology
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 53 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf